open access

Vol 69, No 12 (2011)
Original articles
Published online: 2011-12-15
Submitted: 2012-12-28
Get Citation

The effects of intracoronary delivery of mononuclear bone marrow cells in patients with myocardial infarction: a two year follow−up results

Michał Plewka, Maria Krzemińska-Pakuła, Jan Z. Peruga, Piotr Lipiec, Małgorzata Kurpesa, Karina Wierzbowska-Drabik, Anna Korycka-Wołowiec, Jarosław D. Kasprzak
Kardiol Pol 2011;69(12):1234-1240.

open access

Vol 69, No 12 (2011)
Original articles
Published online: 2011-12-15
Submitted: 2012-12-28

Abstract

Background: Transplantation of bone marrow stem cells (BMSC) is a new method of prevention of left ventricular (LV) remodelling in post-infarction patients. Studies published to date point to LV systolic and diastolic function improvement following this therapy however only a few studies assessed the long-term effects of BMSC.
Aim: To assess the 2 year prognosis in patients with anterior myocardial infarction (MI) treated with BMSC transplantation in the acute phase.
Methods: The study group consisted of 60 patients with first anterior ST-segment elevation MI (STEMI), treated with primary percutaneous angioplasty, with baseline LV ejection fraction (LVEF) < 40%, who were randomly assigned to undergo BMSC transplantation on day 7 of the STEMI (40 patients, BMSC group) or to receive standard treatment (20 patients, control group). In all the patients echocardiography was performed at baseline and after 1, 3, 6, 12 and 24 months. The composite end-point (death, MI, admission for heart failure or repeat revascularisation) was assessed after 2 years of follow-up.
Results: Absolute increase of LVEF compared to baseline values was higher in the BMSC group than in the control group. The LVEF increase in BMSC group at 1 month was 7.1% (95% CI 3.1–11.1%), at 6 months — 9.3% (95% CI 5.3–13.3%), at 12 months — 11.0% (95% CI 6.2–13.3%) and at 24 months — 10% (95% CI 7.2–12.1%). In the control group, LVEF increase was 3.7% (95% CI 2.3–9.7%) at 1 month, 4.7% (95% CI 1.2–10.6%) at 6 months, 4.8% (95% CI 1.5–11.0%) at 12 months and 4.7% (95% CI 1.4–10.7%) at 24 months. The composite end-point occurred significantly more frequently in the control group (55%) than in the BMSC group (23%): OR 2.72; 95% CI 1.06–7.02, p = 0.015.
Conclusions: Treatment with mononuclear bone marrow cells on day 7 of the first anterior MI in patients with significant baseline systolic dysfunction improves 2-year outcome.
Kardiol Pol 2011; 69, 12: 1234–1240

Abstract

Background: Transplantation of bone marrow stem cells (BMSC) is a new method of prevention of left ventricular (LV) remodelling in post-infarction patients. Studies published to date point to LV systolic and diastolic function improvement following this therapy however only a few studies assessed the long-term effects of BMSC.
Aim: To assess the 2 year prognosis in patients with anterior myocardial infarction (MI) treated with BMSC transplantation in the acute phase.
Methods: The study group consisted of 60 patients with first anterior ST-segment elevation MI (STEMI), treated with primary percutaneous angioplasty, with baseline LV ejection fraction (LVEF) < 40%, who were randomly assigned to undergo BMSC transplantation on day 7 of the STEMI (40 patients, BMSC group) or to receive standard treatment (20 patients, control group). In all the patients echocardiography was performed at baseline and after 1, 3, 6, 12 and 24 months. The composite end-point (death, MI, admission for heart failure or repeat revascularisation) was assessed after 2 years of follow-up.
Results: Absolute increase of LVEF compared to baseline values was higher in the BMSC group than in the control group. The LVEF increase in BMSC group at 1 month was 7.1% (95% CI 3.1–11.1%), at 6 months — 9.3% (95% CI 5.3–13.3%), at 12 months — 11.0% (95% CI 6.2–13.3%) and at 24 months — 10% (95% CI 7.2–12.1%). In the control group, LVEF increase was 3.7% (95% CI 2.3–9.7%) at 1 month, 4.7% (95% CI 1.2–10.6%) at 6 months, 4.8% (95% CI 1.5–11.0%) at 12 months and 4.7% (95% CI 1.4–10.7%) at 24 months. The composite end-point occurred significantly more frequently in the control group (55%) than in the BMSC group (23%): OR 2.72; 95% CI 1.06–7.02, p = 0.015.
Conclusions: Treatment with mononuclear bone marrow cells on day 7 of the first anterior MI in patients with significant baseline systolic dysfunction improves 2-year outcome.
Kardiol Pol 2011; 69, 12: 1234–1240
Get Citation

Keywords

mononuclear bone marrow cells; stem cells; ST-segment elevation myocardial infarction; left ventricular function; prognosis

About this article
Title

The effects of intracoronary delivery of mononuclear bone marrow cells in patients with myocardial infarction: a two year follow−up results

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 69, No 12 (2011)

Pages

1234-1240

Published online

2011-12-15

Bibliographic record

Kardiol Pol 2011;69(12):1234-1240.

Keywords

mononuclear bone marrow cells
stem cells
ST-segment elevation myocardial infarction
left ventricular function
prognosis

Authors

Michał Plewka
Maria Krzemińska-Pakuła
Jan Z. Peruga
Piotr Lipiec
Małgorzata Kurpesa
Karina Wierzbowska-Drabik
Anna Korycka-Wołowiec
Jarosław D. Kasprzak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl